Karyopharm to Participate at Upcoming Investor Conferences
Karyopharm to Participate at Upcoming Investor Conferences
NEWTON, Mass., Sept. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:
2024年9月3日，马萨诸塞州牛顿——Karyopharm Therapeutics Inc.（纳斯达克：KPTI）一家在商业化阶段的药品公司，开创了新型癌症治疗方法，今天宣布该公司的高级管理团队将参加9月份以下投资者会议：
H.C. Wainwright 26th Annual Global Investment Conference
Format: Podium presentation
Date: Tuesday, September 10, 2024
Time: 9:00 a.m. ET
汉肯莱特第26届全球投资大会
格式：讲台演讲
日期：2024年9月10日星期二
时间：美国东部时间上午9:00
Baird 2024 Global Healthcare Conference
Format: Fireside chat
Date: Wednesday, September 11, 2024
Time: 10:50 a.m. ET
贝尔德2024全球医疗保健大会
形式：座谈会
日期：2024年9月11日，星期三
时间：上午10:50 ET
A live webcast of these events, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, , and will be available for replay following the event.
这些活动的现场网络直播以及配套幻灯片可以在公司网站的"事件和演示"栏目下访问，并且将在活动结束后提供重播。
About Karyopharm Therapeutics
关于Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of exU.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit , and follow us on LinkedIn and on X at @Karyopharm.
Karyopharm Therapeutics Inc.（纳斯达克：KPTI）是一家商业药品公司，其致力于开发先驱性的癌症治疗方法，其动力源于对患癌症患者非凡的力量和勇气的信仰。自创立以来，Karyopharm一直是口服复合物应对核蛋白质输运异常的行业领导者，这是肿瘤发生的基本机制。 Karyopharm的主要化合物和首个一类口服exportin 1（XPO1）抑制剂XPOVIO（selinexor）已获得美国批准，并由该公司在三种肿瘤适应症中销售。 它还在越来越多的境外领域和国家获得了各种适应症的监管批准，包括欧洲、中国和英国（作为NEXPOVIO）。 Karyopharm的重点管道针对多种高需求肿瘤的适应症，包括多发性骨髓瘤、子宫内膜癌、骨髓纤维化和弥漫性大B细胞淋巴瘤（DLBCL）。 获得更多关于我们人员、科学和管道的信息，请访问网站，并在LinkedIn和X上关注我们@Karyopharm。
XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
XPOVIO和NEXPOVIO是Karyopharm Therapeutics Inc.的注册商标。本新闻稿中提到的任何其他商标均为其各自所有者的财产。
SOURCE Karyopharm Therapeutics Inc.
消息来源：Karyopharm Therapeutics Inc.